Aclaris Therapeutics submits Investigational New Drug Application for ATI-450
Aclaris Therapeutics announced it has submitted an IND Application to the FDA for ATI-450, an oral MK2 inhibitor, for treatment of rheumatoid arthritis. If the IND is allowed by the FDA, Aclaris plans to initiate a Phase 1 clinical trial of ATI-450 in the second half of 2019. April 25, 2019